Acceleron intends to use the net proceeds from the offering to conduct clinical trials and associated activities with therapeutic candidates from its existing research pipeline and for general and administrative expenses (including personnel-related costs), capital expenditures and working capital and other general corporate purposes, including potential acquisitions of rights to additional programs from third parties.
The securities described above are being offered by Acceleron pursuant
to its registration statement on Form S-3 filed with the
This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in the offering, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
Acceleron is a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare hematologic, neuromuscular, and pulmonary diseases. Its pioneering research and protein engineering platform engages the target-rich TGF-beta superfamily and its remarkable ability to regulate cellular growth and repair.
Under a global partnership with Celgene, Acceleron is in Phase 3 development with luspatercept, a potential first-in-class chronic anemia therapy for the treatment of rare blood diseases. The Company is also advancing a neuromuscular franchise with two distinct Myostatin+ agents, ACE-083 and ACE-2494, and a pulmonary program with a Phase 2 trial of sotatercept planned in pulmonary arterial hypertension. Acceleron has ongoing preclinical research efforts targeting additional indications in these three disease areas where there is significant unmet medical need.
Cautionary Note on Forward-Looking Statements
Certain statements contained in this release, including those relating
to the use of proceeds from the sale of common stock, are
forward-looking statements that involve a number of risks and
uncertainties that could cause actual results to differ materially from
those in the forward-looking statements. These risks and uncertainties
include, but are not limited to, risks and uncertainties associated with
the consummation of the proposed offering and general economic
conditions and other risks identified from time to time in the reports
we file with the
Vice President, Investor Relations and Corporate Communications
News Provided by Acquire Media